Clinical Trial: A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07798947) titled 'A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC' on Aug. 28.

Brief Summary: This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Limited-stage Small-cell Lung Cancer

Intervention: DRUG: SHR-7787 Injection

SHR-7787 injection.

DRUG: SHR-1316

SHR-1316 (Adebrelimab) Injection.

Recruitment Status: NOT_YET_RECRUITING

Sponso...